Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087) [Phase 2]

View source ↗

Summary

Results from the Phase 2 MK-3475-087 (KEYNOTE-087) study of pembrolizumab in relapsed or refractory classical Hodgkin lymphoma have been completed and results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2024-10-29